Bridgeway Capital Management LLC Decreases Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Bridgeway Capital Management LLC trimmed its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 38.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,000 shares of the medical equipment provider's stock after selling 23,100 shares during the period. Bridgeway Capital Management LLC's holdings in Hologic were worth $2,667,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the company. Benson Investment Management Company Inc. purchased a new stake in shares of Hologic in the fourth quarter worth $4,832,000. Principal Financial Group Inc. grew its holdings in shares of Hologic by 0.6% during the fourth quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider's stock worth $19,547,000 after purchasing an additional 1,606 shares in the last quarter. Clean Yield Group grew its holdings in shares of Hologic by 18.9% during the fourth quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider's stock worth $3,291,000 after purchasing an additional 7,266 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in Hologic by 44.7% in the fourth quarter. Nisa Investment Advisors LLC now owns 63,744 shares of the medical equipment provider's stock valued at $4,595,000 after purchasing an additional 19,688 shares in the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its position in Hologic by 11.4% during the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 68,427 shares of the medical equipment provider's stock valued at $4,933,000 after purchasing an additional 6,986 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Hologic Trading Down 2.5%

Hologic stock traded down $1.45 during mid-day trading on Wednesday, reaching $55.67. 1,407,019 shares of the company traded hands, compared to its average volume of 2,919,575. The firm's 50 day moving average price is $59.26 and its 200 day moving average price is $67.94. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The firm has a market capitalization of $12.41 billion, a price-to-earnings ratio of 17.56, a P/E/G ratio of 2.14 and a beta of 0.54. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. The company had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1 billion. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The firm's revenue for the quarter was down 1.2% on a year-over-year basis. During the same period in the prior year, the firm earned $1.03 earnings per share. On average, analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Buying and Selling at Hologic

In other news, Director Martin D. Madaus bought 5,445 shares of the firm's stock in a transaction on Wednesday, May 7th. The stock was acquired at an average cost of $55.24 per share, with a total value of $300,781.80. Following the completion of the acquisition, the director now owns 5,445 shares of the company's stock, valued at approximately $300,781.80. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.88% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently commented on HOLX. StockNews.com cut Hologic from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Royal Bank of Canada dropped their target price on Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a research report on Friday, May 2nd. Evercore ISI decreased their price target on shares of Hologic from $65.00 to $62.00 and set an "in-line" rating on the stock in a research note on Friday, May 2nd. Argus cut shares of Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Finally, Leerink Partnrs lowered shares of Hologic from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. Twelve investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $77.42.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.